BioSpace News Archive

AstraZeneca appears to have taken an interest in Mereo BioPharma and may be considering a buyout, according to speculations published by The Times UK.

The World Trade Organization approved vaccine patent waivers to increase the availability of COVID-19 vaccines to lower-income countries.

Researchers from the Baylor College of Medicine, Stanford School of Medicine and others discovered a molecule produced during exercise in mice that suppresses feeding and obesity.

An FDA advisory committee voted against Acadia Pharmaceutical’s supplemental New Drug Application of Nuplazid tablets for the treatment of Alzheimer’s-related psychosis.

The global structural biology and molecular modeling techniques market is a novel conception in the global healthcare sector and has already made key contributions in obtaining remedies to a number of diseases.

Wilmington, Delaware, United States: According to the report, the global medical sensors market was valued at US$ 15.23 Bn in 2020 and is projected to expand at a CAGR of 9.9% from 2021 to 2028.

The demand in the global immunomodulators market is expected to increment at a potent CAGR during the forecast period of 2017 to 2025, which can be attributed to a number of key factors, such as increasing adoption of monoclonal antibodies, presence of strong pipeline portfolio, strong adoption of TNF-alpha inhibitors and B-cell inhibitors, advancements in the diagnostic tools, and the development of novel therapies using innovative technologies.

Kineta, Inc. announced that it presented the Phase 1/2 clinical trial design and new preclinical data supporting KVA12.1 as a potential treatment for cancer patients with advanced solid tumors at the Tumor Myeloid-Directed Therapies Summit held on June 14-16 in Boston, MA.

Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy.

AUGS/IUGA Scientific Meeting 2022- Renovia Inc. (Renovia), a women-led company that develops digital therapeutics for female pelvic floor disorders, announced today that researchers presented new data supporting the value of the leva® Pelvic Health System in treating female urinary incontinence (UI).